Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.
-
Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.
-
Pluristyx and Breakthrough T1D partner to engineer an immune-cloaked, safety-enabled iPSC line to advance universal islet therapies for type 1 diabetes.
-
Pluristyx signs key clinical use licenses for its iPSC platform, enabling new regenerative and neurological disease therapies.
-
Pluristyx and Solesis partner to launch game-changing standardized organoid kits, powered by iPSC and polymer technologies.
-
Pluristyx & BioLamina partner to accelerate iPSC-based therapies with integrated cell culture solutions, for consistency, scalability & clinical success.